TradeFlare's AI research teams analysed NUVL on 5 market nights between June 1, 2026 and June 17, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| June 17, 2026 | HOLD | $123.39 | — / — | not yet | not yet | Potential $10.6 billion acquisition by GSK provides a clear catalyst. |
| June 16, 2026 | BUY | $123.35 | — / — | not yet | not yet | The market regime is neutral, and while there's a scanner trigger, the directional teams are not bullish, and the technicals are neutral with a bearish volume signal. |
| June 15, 2026 | HOLD | $123.25 | — / — | not yet | not yet | The market regime is neutral, and the stock's technical and fundamental teams are bearish, overriding the scanner's signal. |
| June 12, 2026 | BUY | $123.45 | — / — | not yet | not yet | The current market regime and the stock's technical and risk profile do not support a buy recommendation. |
| June 1, 2026 | BUY | $110.39 | — / — | not yet | not yet | The market regime is neutral, and while NUVL shows technical strength, the strong fundamental bearishness and high risk score necessitate caution. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.